Skip to main content

Table 1 Comparison of the frequency of variants in RNASEL and MSR1 genes in 737 patients with prostate cancer and 511 individuals from control group

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Gene Variant Genotype Number of carriers (frequency) OR 95% CI p
    cases
(n = 737)
No. (%)
controls
(n = 511)
No. (%)
   
RNASEL 1385G>A
(R462Q)
GG 245 (33.3) 177 (34.6) 0.9 0.7–1.2 0.6
   GA 376 (51.0) 252 (49.3) 1.1 0.9–1.3 0.6
   AA 116 (15.7) 82 (16.1) 1.0 0.7–1.3 0.9
  1623T>G
(D541E)
TT 111 (15.1) 84 (16.4) 0.9 0.7–1.2 0.5
   TG 372 (50.5) 259 (50.7) 1.0 0.8–1.2 1.0
   GG 254 (34.4) 168 (32.9) 1.1 0.8–1.4 0.6
MSR1 945C>G
(P275A)
CC 663 (90.0) 474 (92.8) 0.7 0.5–1.1 0.1
   CG 74 (10.0) 37 (7.2) 1.4 0.9–2.2 0.1
  999C>T
(R293X)
CC 725 (98.4) 503 (98.4) 1.0 0.4–2.4 1.0
   CT 12 (1.6) 8 (1.6) 1.0 0.4–2.6 1.0
  1. CI – confidence interval; OR – odds ratio; p – p-value